| 14 |
Vachharajani V, Mccall CE. Epigenetic and metabolic programming of innate immunity in sepsis [J]. Innate Immun, 2019, 25(5):267-279.
|
| 15 |
Jensen IJ, Sjaastad FV, Griffith TS, et al. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired t cell immunity [J]. J Immunol, 2018, 200(5):1543-1553.
|
| 16 |
Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses [J]. Lancet, 2020, 395(10235): 1517-1520.
|
| 17 |
Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients [J]. EBioMedicine, 2020, 55: 102763.
|
| 18 |
Copaescu A, Smibert O, Gibson A, et al. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection [J]. J Allergy Clin Immunol, 2020, 146(3):518-534
|
| 19 |
Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers [J]. Arch Pathol Lab Med, 2020, 144(12): 1465-1474.
|
| 20 |
Wu ZY, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [J]. JAMA, 2020, 323(13):1239-1242.
|
| 21 |
Wu HP, Chung K, Lin CY, et al. Associations of T helper 1, 2, 17 and regulatory T lymphocytes with mortality in severe sepsis [J]. Inflamm Res, 2013, 62(8): 751-763.
|
| 22 |
Li J, Li M, Su L, et al. Alterations of T helper lymphocyte subpopulations in sepsis, severe sepsis, and septic shock: a prospective observational study [J]. Inflammation, 2015, 38(3): 995-1002.
|
| 23 |
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses [J]. Nature, 2020, 586(7830): 594-599.
|
| 24 |
Xue M, Xie J, Liu L, et al. Early and dynamic alterations of Th2/Th1 in previously immunocompetent patients with community-acquired severe sepsis: a prospective observational study [J]. J Transl Med, 2019, 17(1): 57.
|
| 25 |
Vyas N, Kurian SJ, Bagchi D, et al. Vitamin D in prevention and treatment of COVID-19: current perspective and future prospects [J]. J Am Coll Nutr, 2020, 1: 1-14.
|
| 26 |
Guo J, Tao W, Tang D, et al. Th17/regulatory T cell imbalance in sepsis patients with multiple organ dysfunction syndrome: attenuated by high-volume hemofiltration [J]. Int J Artif Organs, 2017, 40(11): 607-614.
|
| 27 |
肖漓, 马锡慧. 淋巴细胞亚群成员研究进展 [J]. 中华细胞与干细胞杂志, 2017, 7(3): 168.
|
| 28 |
Tatura R, Zeschnigk M, Hansen W, et al. Relevance of Foxp3(+) regulatory T cells for early and late phases of murine sepsis [J]. Immunology, 2015, 146(1): 144-156.
|
| 29 |
Ghazavi A, Ganji A, Keshavarzian N, et al. Cytokine profile and disease severity in patients with COVID-19 [J]. Cytokine. 2020,137: 155323.
|
| 30 |
Cavassani KA, Carson WFT, Moreira AP, et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth [J]. Blood, 2010, 115(22): 4403-4411.
|
| 31 |
Gupta DL, Bhoi S, Mohan T, et al. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with post traumatic sepsis [J]. Cytokine, 2016, 88: 214-221.
|
| 32 |
Greenberg JA, Hrusch CL, Jaffery MR, et al. Distinct T-helper cell responses to Staphylococcus aureus bacteremia reflect immunologic comorbidities and correlate with mortality [J]. Crit Care, 2018, 22(1): 107.
|
| 33 |
Hohlstein P, Gussen H, Bartneck M, et al. Prognostic relevance of altered lymphocyte subpopulations in critical illness and sepsis [J]. J Clin Med, 2019, 8(3):353.
|
| 34 |
Danahy DB, Strother RK, Badovinac VP, et al. Clinical and experimental sepsis impairs CD8 T-cell-mediated immunity [J]. Crit Rev Immunol, 2016, 36(1): 57-74.
|
| 35 |
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Respir Med, 2020, 8(4): 420-422.
|
| 36 |
Marshall JC. Special issue: sepsis why have clinical trials in sepsis failed? [J]. Trends Mol Med, 2014, 20(4): 195-203.
|
| 37 |
Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R, et al. Defining immunological dysfunction in sepsis: A requisite tool for precision medicine [J]. J Infect, 2016, 72(5): 525-536.
|
| 38 |
Kumar V. T cells and their immunometabolism: A novel way to understanding sepsis immunopathogenesis and future therapeutics [J]. Eur J Cell Biol, 2018, 97(6): 379-392.
|
| 39 |
Ding RY, Meng YL, Ma XC. The central role of the inflammatory response in understanding the heterogeneity of sepsis-3 [J]. Biomed Res Int, 2018(2018): 5086516.
|
| 1 |
Finkelsztein EJ, Jones DS, Ma KC, et al. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit [J]. Crit Care, 2017, 21(1): 73.
|
| 2 |
Fisher CJJr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group [J]. N Engl J Med, 1996, 334(26): 1697-1702.
|
| 3 |
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy [J]. Nat Rev Immunol, 2013, 13(12): 862-874.
|
| 4 |
Jamme M, Daviaud F, Charpentier J, et al. Time course of septic shock in immunocompromised and nonimmunocompromised patients [J]. Crit Care Med, 2017, 45(12): 2031-2039.
|
| 5 |
Tolsma V, Schwebel C, Azoulay E, et al. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile [J]. Chest, 2014, 146(5): 1205-1213.
|
| 6 |
Bhan C, Dipankar P, Chakraborty P, et al. Role of cellular events in the pathophysiology of sepsis [J]. Inflamm Res, 2016, 65(11): 853-868.
|
| 7 |
Van Der Poll T, Van De Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets [J]. Nat Rev Immunol, 2017, 17(7): 407-420.
|
| 8 |
Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis [J]. Semin Immunopathol, 2017, 39(5): 517-528.
|
| 9 |
Cuenca AG, Gentile LF, Lopez MC, et al. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients [J]. Crit Care Med, 2013, 41(5): 1175-1185.
|
| 10 |
苏和毅, 莫泽珣, 陈珍, 等. ICU严重免疫失衡疾病——持续炎症-免疫抑制-分解代谢综合征 [J]. 中华危重病急救医学, 2017, 29(8): 760-764.
|
| 11 |
Bahar I, Elay G, Baskol G, et al. Increased DNA damage and increased apoptosis and necrosis in patients with severe sepsis and septic shock [J]. J Crit Care, 2018, 43: 271-275.
|
| 12 |
Liu D, Cao S, Zhou Y, et al. Recent advances in endotoxin tolerance [J]. J Cell Biochem, 2019, 120(1): 56-70.
|
| 13 |
Feng Y, Liu B, Zheng X, et al. The protective role of autophagy in sepsis [J]. Microb Pathog, 2019, 131: 106-111.
|